Clinical trial
Milk-derived Gangliosides as Novel Anti-inflammatory Therapy for Inflammatory Bowel Disease
NCT02139709 is registered in ClinicalTrials.gov with University of Alberta as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Milk-derived Gangliosides as Novel Anti-inflammatory Therapy for Inflammatory Bowel Disease
- Lead sponsor
- University of Alberta
- Phase
- Phase 1
- Overall status
- Withdrawn
- Start date
- January 31, 2007
- Completion date
- August 31, 2015
- Enrollment
- 0 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
inflammatory bowel disease